Table 2.
Summary of differences between IN/MLV-boosted and IN/inactivated-boosted calves before and during challenge.
| Sample (units) | Outcome | Treatment group | Median | Range | P-value* |
|---|---|---|---|---|---|
| BRSV specific IgG (ELISA units) | Change in BRSV serum specific | IN/MLV-boosted | 76.7 | 56.0 to 99.7 | 0.04 |
| IgG ≤ 24 h old (1st vaccination) to 2 mo of age (post boost) | IN/inactivated-boosted | 51.9 | 36.1 to 99.1 | ||
| Change in BRSV serum specific | IN/MLV-boosted | 3.3 | 0.0 to 29.9 | < 0.0001 | |
| IgG from baseline (Day 0) to Day 7 | IN/inactivated-boosted | 46.9 | 13.1 to 56.2 | ||
| BRSV specific IgA (ELISA units) | Change in BRSV specific IgA from baseline (Day 0) to Day 5 | IN/MLV-boosted | 1.4 | −2.0 to 12.9 | 0.73 |
| IN/inactivated-boosted | 1.0 | −5.2 to 16.8 | |||
| Change in BRSV specific IgA from baseline (Day 0) to Day 7 | IN/MLV-boosted | 1.5 | −4.5 to 11.5 | ||
| IN/inactivated-boosted | 2.2 | −14.5 | 0.73 | ||
| Change in BRSV specific IgA from Day 5 to Day 7 | IN/MLV-boosted | −0.27 | −9.41 to 13.0 | 0.83 | |
| IN/inactivated-boosted | −2.4 | −11.3 to 7.0 | |||
| BRSV neutralization titers (NT) (geometic means) | Change in BRSV NT from baseline (Day 0) to Day 7 | IN/MLV-boosted | 1 | −1 to 6 | < 0.0001 |
| IN/inactivated-boosted | 5 | 3 to 7 |
*
Statistical significance adjusted to P ≤ 0.01 due to multiple comparisons.